FASTING MIMICKING TECHNOLOGY
Live / Applied — Fourth extension granted (statement of use) (as of 19 Feb 2025)
What this means for you
Not registered yet, but its 14 Apr 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97364195
- Mark type
- Stylized text
- Filed
- 14 Apr 2022
- Published for opposition
- 06 Jun 2023
- Attorney of record
- THOMAS J SPEISS III
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, namely, epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; Pharmaceutical preparations, namely, epigenetic drugs targeting arginine methylation in cancer; pharmaceutical preparations in the nature of inhibitors of arginine methylation for the treatment of cancer; pharmaceutical preparations in the nature of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; cancer treatment vaccines; therapeutic vaccines for treating cancer; cancer therapy subsection vaccines; pharmaceutical compounds for the treatment, diagnosis, detection and prevention of cancer; pharmaceutical preparations for the treatment, diagnosis, detection and prevention of cancer; Pharmaceutical preparations, namely, biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer
- Class 042 — Scientific and technological services: Research and development services in the pharmaceutical and biotechnology fields; medical research and development services in the pharmaceutical and biotechnology fields; scientific research and development services; pharmaceutical research and development services; research and development in the field of epigenetic drugs for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of epigenetic drugs targeting arginine methylation in cancer; research and development in the field of inhibitors of arginine methylation for the treatment of cancer; research and development in the field of inhibitors of protein arginine methyl-transferase (PRMT) for the treatment of cancer; research and development in the field of cancer treatment vaccines, therapeutic vaccines for treating cancer and cancer therapy subsection vaccines; research and development in the field of compounds for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of pharmaceutical products, preparations and substances for the treatment, diagnosis, detection and prevention of cancer; research and development in the field of biological preparations and substances for the treatment, diagnosis, detection and prevention of cancer; consultancy, advisory and information services relating to and connected with the aforementioned services
Owner
- L-Nutra Inc., Culver City, CA, US
- L-Nutra Inc., Plano, TX, US
Prior registrations
Prosecution history
- 17 Mar 2026 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 17 Mar 2026 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 17 Mar 2026 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 17 Mar 2026 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 17 Mar 2026 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 16 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 20 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Feb 2025 — SOU EXTENSION 4 GRANTED
- 19 Feb 2025 — SOU EXTENSION 4 FILED
- 19 Feb 2025 — SOU TEAS EXTENSION RECEIVED
- 20 Oct 2024 — SOU EXTENSION 3 GRANTED
- 20 Oct 2024 — SOU EXTENSION 3 FILED
- 20 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 12 Sept 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 12 Sept 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED